198 related articles for article (PubMed ID: 29199176)
1. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
[TBL] [Abstract][Full Text] [Related]
2. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
3. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
5. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
7. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
10. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
11. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
13. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
[No Abstract] [Full Text] [Related]
14. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
15. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic advances in the treatment of hairy cell leukemia.
Andrey J; Saven A
Leuk Res; 2001 May; 25(5):361-8. PubMed ID: 11301103
[No Abstract] [Full Text] [Related]
17. Advances in the treatment of hairy-cell leukaemia.
Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases.
Yu YB; Li CY; Chen CC; You JY; Chau WK; Hsu HC; Gau JP; Chen PM; Ho CH
J Chin Med Assoc; 2007 Dec; 70(12):551-5. PubMed ID: 18194897
[TBL] [Abstract][Full Text] [Related]
19. [Recurrent somatic mutation in hairy cell leukemia].
Sári E; Nagy Z; Demeter J
Orv Hetil; 2013 Jan; 154(4):123-7. PubMed ID: 23335721
[TBL] [Abstract][Full Text] [Related]
20. The treatment of hairy cell leukemia: an update.
Golomb HM; Ratain MJ; Mick R; Daly K
Leukemia; 1992; 6 Suppl 2():24-7. PubMed ID: 1349662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]